Topic: manufacturing expansion
Nexus Pharmaceuticals has moved forward the first phase of a 10-year, $250 million project to build out its sterile drug production operations.
Catalent is buying a site in Italy from Bristol-Myers Squibb that handles biologics along with old-school solid-dose production.
Boehringer Ingelheim has invested €225 million on inhaler production with a new plant in Spain and expanded lines in Germany.
Aldevron unveiled plans to expand its North Dakota headquarters into a 14-acre campus.
GlaxoSmithKline will unload an API plant to Thermo Fisher Scientific for €90 million. The U.S. company says it is glad to get it.
Merck & Co., which has been riding a wave of Gardasil sales, will invest $1 billion and add 100 jobs to expand production.
Lilly plans a $91 million plant expansion in Indianapolis, and a $7 million tax abatement tied to the project has generated some debate.
Regeneron is supersizing a campus expansion in New York, investing $800 million and adding 1,500 jobs.
Shionogi’s flu drug won Japanese approval; Sun Pharma's Halol plant was cited by the FDA; EpimAb hired a top Novartis researcher as CMO; plus more.
Merck KGaA, which has been rapidly building up its manufacturing and distribution capabilities in China, says it will now expand further in Asia.